Literature DB >> 20234984

[Long-term outcome after penetrating keratoplasty for keratoconus--impact of preoperative corneal curvature and best corrected visual acuity on the functional results].

A Preclik1, A Langenbucher, B Seitz, C Cursiefen.   

Abstract

BACKGROUND: The purpose of this study was to assess the long-term functional visual results of penetrating keratoplasty for keratoconus and to assess the impact of the patient's preoperative corneal curvature and preoperative best spectacle corrected visual acuity (BCVA) on the refractive outcome. PATIENTS/
MATERIAL AND METHODS: In this retrospective study 456 patients with keratoconus who received central round penetrating keratoplasty (PK) were examined 1/3/5/8/ > 9 years postoperatively. Patients were divided retrospectively into subgroups: first based on their preoperative keratometric (K-) readings: group I.1, < 50 diopters (D) (n = 21); group I.2, 50 - 60 D (n = 102); group I.3, > or = 60 D (n = 164); group I.4, irregular corneal shape with non-measurable K-reading (n = 158), group I.0 unknown preoperative K-reading (n = 58) and then based on the preoperative BCVA: group II.0 BCVA < or = 0.1 (n = 204); group II.1 BCVA > 0.1 (n = 263). The trephination was performed using the 193-nm excimer laser and the transplanted cornea was fixed by a double running cross-stitch suture. The outcome measures included keratometric central refractive equivalent (KEQ), keratometric astigmatism (AST), spherical equivalent (SEQ), refractive cylinder (CYL), best corrected visual acuity (BCVA), surface regularity index (SRI), surface asymmetry index (SAI)topographic central power equivalent (T-EQ) and topographic astigmatism (T-AST).
RESULTS: Five/eight years postoperatively, BCVA was 0.71/0.73; KEQ was 43.4/44.4 D; SEQ -1.6/-0.8; AST was 3.4/3.6 D; CYL was 3.0/3.0 D, SRI was 0.88/0.83; SAI was 0.78 / 0.78; T-EQ was 44.5/44.9 D and T-AST was 4.0/4.2 D. The results for BCVA of patients whose preoperative BCVA measured < or = 0.1 were significantly worse than the results of patients with better preoperative BCVA. Other comparisons among the subgroups revealed no further significant differences for any parameter tested.
CONCLUSIONS: In our study the long-term results of BCVA after penetrating keratoplasty for keratoconus seem to be quite stable (0.7). This indicates that corneal transplantation is a viable option in the clinical course of keratoconus. Furthermore, the outcome of PK for keratoconus seems to be independent of the patient's preoperative corneal curvature. In contrast, unfavourable BCVA preoperatively may be a negative predictor for the visual outcome. Georg Thieme Verlag KG Stuttgart, New York.

Entities:  

Mesh:

Year:  2010        PMID: 20234984     DOI: 10.1055/s-0028-1109739

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  5 in total

1.  [Postkeratoplasty astigmatism: comparison of three suturing techniques].

Authors:  I Naydis; M Klemm; A Hassenstein; G Richard; T Katz; S J Linke
Journal:  Ophthalmologe       Date:  2011-03       Impact factor: 1.059

Review 2.  [Perspectives of laser-assisted keratoplasty: current overview and first preliminary results with the picosecond infrared laser (λ = 3 µm)].

Authors:  S J Linke; L Ren; A Frings; J Steinberg; W Wöllmer; T Katz; R Reimer; N O Hansen; N Jowett; G Richard; R J Dwayne Miller
Journal:  Ophthalmologe       Date:  2014-06       Impact factor: 1.059

3.  [Deep Anterior Lamellar Keratoplasty : Experiences and results of the first 100 consecutive DALK from the University Eye Hospital of Cologne].

Authors:  F Schaub; L M Heindl; P Enders; S Roters; B O Bachmann; C Cursiefen
Journal:  Ophthalmologe       Date:  2017-11       Impact factor: 1.059

Review 4.  [Perspectives of deep anterior lamellar keratoplasty].

Authors:  C Cursiefen; L M Heindl
Journal:  Ophthalmologe       Date:  2011-09       Impact factor: 1.059

Review 5.  [Update: Deep anterior lamellar keratoplasty (DALK) for keratoconus. When, how and why].

Authors:  C Cursiefen; F Schaub; B Bachmann
Journal:  Ophthalmologe       Date:  2016-03       Impact factor: 1.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.